Belgian biotech Celyad (Euronext Brussels: CYAD) has appointed gene therapy expert David Gilham as vice-president of research & development.
Dr Gilham will take up his role in September, and in order to do so will resign from Celyad’s Immuno-Oncology Scientific Advisory Board the previous month.
The company has positioned itself as a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze